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OBJECTIVES The goal of this study was to identify subgroups of arrhythmia patients who do not benefit
from use of the implantable cardiac defibrillator (ICD).
BACKGROUND Treatment of serious ventricular arrhythmias has evolved toward more common use of the
ICD. Since estimates of the cost per year of life saved by ICD therapy vary from $25,000 to
perhaps $125,000, it is important to identify patient subgroups that do not benefit from the
ICD.
METHODS Data for 491 ICD patients enrolled in the Antiarrhythmics Versus Implantable Defibrillators
Study were used to create a hazards model relating baseline factors to time to first recurrent
arrhythmia. The model was used to predict the hazard for recurrent arrhythmia among all trial
patients. A priori cut points provided lower and higher recurrent arrhythmia risk strata. For
each stratum the incremental years of life due to ICD versus antiarrhythmic drug therapy
were calculated.
RESULTS Factors that predicted recurrent arrhythmia were: ventricular tachycardia as the index
arrhythmia, history of cerebrovascular disease, lower left ventricular ejection fraction, a history
of any tachyarrhythmia before the index event and the absence of revascularization after the
index event. Survival times (over a follow-up of three years) were identical in each arm of the
lowest risk sextile (survival advantage 0.03 6 0.12 [se] years), while the survival advantage for
patients above the first sextile was 0.27 6 0.07 (se) years (two-sided p 5 0.05).
CONCLUSIONS Patients presenting with an isolated episode of ventricular fibrillation in the absence of
cerebrovascular disease or history of prior arrhythmia who have undergone revascularization
or who have moderately preserved left ventricular function (left ventricular ejection fraction .
0.27) are not likely to benefit from ICD therapy compared with amiodarone therapy. (J Am
Coll Cardiol 2001;37:1093–9) © 2001 by the American College of Cardiology
Treatment of serious ventricular arrhythmias has evolved
toward more common use of the implantable cardiac defi-
brillator (ICD). A number of randomized trials have now
reported a reduction in mortality ranging between 20% and
40% among patients treated with an ICD compared with
patients treated with amiodarone or other antiarrhythmic
therapies (1–4). Since estimates of the cost per year of life
saved by ICD therapy vary from $25,000 to perhaps
$125,000 (5,6), it is important to identify patient sub-
groups—if they exist—that do not benefit from the ICD (7).
During planning for the Antiarrhythmics Versus Im-
plantable Defibrillators study (AVID), we recognized that
stored electrograms in ICDs provide natural history data
that can be used to investigate whether there are important
predictors of arrhythmia recurrence among baseline vari-
ables. If it is possible to find baseline criteria identifying
patients at low risk for recurrent arrhythmia, then we can
evaluate how those patients would have survived had they
not received an ICD by examining mortality of the corre-
sponding group in the drug arm. If little or no survival
advantage of the ICD was found, then this would constitute
a subgroup that might do well without an ICD, thus
avoiding potential complications of the ICD and yielding
substantial cost savings.
METHODS
Of the 1,016 patients enrolled in AVID, 507 patients were
randomized to ICD and 509 patients were randomized to
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antiarrhythmic drugs (AAD) (95% were discharged on
amiodarone). Nineteen patients who died during the base-
line hospital stay (9 in the ICD and 10 in the AAD arms)
were excluded from this analysis. There were seven patients
in the ICD arm excluded because they were discharged
without an ICD. Data for the remaining 491 ICD patients
were entered into a proportional hazards failure time model
to identify baseline factors (that is, patient characteristics,
histories and therapies and procedures up to the time of
baseline hospital discharge) that predicted time to first
recurrent arrhythmia. The time to first recurrent arrhythmia
has the advantage that ICD patients were generally antiar-
rhythmic drug-free until that time (only 19 patients in the
ICD arm were placed on antiarrhythmic drugs before the
first recurrent arrhythmia). An end point of recurrent
arrhythmia was defined as: 1) any ICD therapy (either
antitachycardia pacing [ATP] or shock) for ventricular
fibrillation (VF) or ventricular tachycardia (VT) docu-
mented by the ICD stored electrogram; 2) an episode of
VF or VT identified by hospitalization for recurrent ar-
rhythmia or out-of-hospital emergency care, documented
by emergency medical personnel with external monitoring;
or 3) death classified by the death events committee as
arrhythmic (8).
We used the resulting model to predict the hazard for
recurrent arrhythmia among all patients regardless of treat-
ment assignment. Six patients (two in the ICD and four in
the AAD arms) had to be excluded because data were
missing on factors found to be predictive of recurrence of
arrhythmia. We chose to use the sextiles of the hazard
distribution as a priori cut points based on our belief that
subgroups smaller than 10% to 15% of the population for
whom the benefit of ICD was questionable would be of
little practical importance. A priori cut points reduce the
problem of using the “best” cut point based on the data, and
sextiles gave us potential cut points of 16.7%, 33.4% and
50.1%—reasonable portions of the population. For each
stratum defined by the sextile cut point, estimates of the
mortality distributions and, hence, estimates of the mean
survival time and associated standard error were computed
in the ICD and AAD arms (ostensibly equivalent because of
randomization) by the Kaplan-Meier method, and, from
these, the incremental years of life due to ICD versus AAD
therapy were calculated. Although randomization was ter-
minated in April of 1997, for analysis of factors predictive of
time to arrhythmia recurrence in the ICD arm, we included
the observational follow-up period from April 7, 1997
through August 31, 1998, which allowed a minimum
follow-up of 15 months and a maximum of five years.
However, survival was compared only during the follow-up
obtained until the trial was terminated on April 7, 1997, to
avoid the impact that implantation of ICDs in the drug arm
might create when the trial was terminated. Survival was
truncated at three years because very few patients were
followed in the trial beyond three years.
RESULTS
By three years a recurrent arrhythmia occurred in 313
(63.7%) of the 491 ICD patients. These were identified by
ICD shock for VF in 53 (16.9%), ICD shock for VT in 166
(53.0%), ATP for VT in 67 (21.4%), VF/VT documented
by hospital or EMS recordings in 17 (5.4%) and death
classified as arrhythmic in 10 (3.2%). In the proportional
hazards model, factors that contributed to prediction of
recurrent arrhythmia in the ICD group were: VT as the
index arrhythmia, history of cerebrovascular disease, lower
left ventricular ejection fraction (LVEF), a history of any
tachyarrhythmia (including atrial fibrillation) before the
index event and the absence of revascularization, either
coronary artery bypass grafting or percutaneous transluminal
coronary angiography, after the index event during baseline
hospitalization (Table 1). The lowest risk (of recurrent
arrhythmia) sextile in this model consists mostly (78.9%) of
patients whose index arrhythmia was VF, with no prior
arrhythmia, no cerebrovascular disease and either: 1) revas-
cularization, or 2) no revascularization and LVEF .27%.
Estimates of the time to recurrent arrhythmia are displayed
in Figure 1. Over a mean 2.6 years (range 0 to 5.2) of
follow-up, 35.6% of ICD patients in the first sextile had a
recurrent arrhythmia compared with 70.2% of ICD patients
in the second through sixth sextiles. Estimates of survival by
the treatment arm for the first and second through sixth
sextiles are displayed in Figure 2. Patients in the lowest
sextile for risk of recurrent arrhythmia had identical mean
survival times (over a follow-up of three years) in each arm
(survival difference 0.03 6 0.12 [se] years), while the
survival advantage for patients above the first sextile was
0.27 6 0.07 [se] years over a follow-up period of three years
(two-sided p 5 0.05). Use of any other sextile as a cut point
did not provide significant differential incremental survival
estimates; for example, use of the second sextile as a cut
point yielded survival differences of 0.16 6 0.10 years in the
first and second sextiles and 0.26 6 0.08 years in the third
through sixth sextiles. The recurrent arrhythmia rates and
the mean survival time to three years for each sextile are
shown in Table 2.
Baseline characteristics of the subgroup defined by the
first sextile identified as “potentially not benefiting” from an
Abbreviations and Acronyms
AAD 5 antiarrhythmic drug
ATP 5 antitachycardia pacing
AVID 5 Antiarrhythmics Versus Implantable
Defibrillators study
EF 5 ejection fraction
ICD 5 implantable cardioverter defibrillator
LVEF 5 left ventricular ejection fraction
rh 5 relative hazards
VF 5 ventricular fibrillation
VT 5 ventricular tachycardia
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ICD are shown in Table 3. As expected from the prediction
model, there are substantial differences in a number of
characteristics between the first and higher sextiles: LVEF:
46.8% versus 28.6%; index arrhythmia VF: 92.2% versus
34.1%; no prior tachyarrhythmias: 89.8% versus 29.5%; and
history of cerebrovascular disease: 0.6% versus 17.0%. Many
other factors, such as a history of congestive heart failure,
are also different, but not independently. Procedures during
the index hospitalization and therapies at discharge from the
index hospitalization are shown in Table 4. Revasculariza-
tion during the index hospitalization was three times as
common in the first sextile (25% vs. 8%). Although some
procedures and discharge therapies differed between the first
and higher sextile groups, differences in use by treatment
arm were relatively the same in the sextile groups, with the
possible exception of calcium channel blockers.
DISCUSSION
A substantial subgroup (16.9%) of AVID patients has been
identified for whom the ICD rendered no survival advan-
tage over amiodarone during three years of follow-up. This
finding needs to be verified in an independent sample.
Unfortunately, the AVID registry cannot be used for this
purpose because LVEF was obtained on only a small subset
of the registry patients, and no data on cerebrovascular
history were gathered. The predictors of arrhythmia recur-
rence in AVID were: 1) measures of arrhythmia based on
historical information or the index event; 2) ejection fraction
(EF) (related to the general level of left ventricular dysfunc-
tion); 3) a history of cerebrovascular disease and 4) revas-
cularization after the index event but during hospitalization
for the index event and declared to be necessary before
randomization. A patient’s risk for arrhythmia recurrence
can be determined from the formula in Table 1, but nearly
80% of the low-risk patients were survivors of VF with no
prior arrhythmia, no cerebrovascular disease and either had
an EF .27% or were revascularized after the VF. These
criteria are not as simple as the 35% EF cut off Domanski et
al. ( 9) derived from the AVID data. However, the report by
Domanski et al. (9) does not recognize the strong correla-
Table 1. Factors Predictive of Recurrent Arrhythmias Among 480 ICD Recipients
p Relative Hazard* 95% CI
Index Arrhythmia 0.0001
Ventricular fibrillation 1
Syncopal ventricular tachycardia 1.47 (1.06, 2.03)
Symptomatic VT, EF # 40% 2.17 (1.66, 2.83)
Hx cerebrovascular disease 0.008 1.54 (1.12, 2.11)
LVEF 0.0001 1.22 (per 10%2) (1.10, 1.35)
Hx of any prior tachyarrhythmia 0.0001 1.6 (1.31, 2.08)
Revascularization (during baseline hosp. stay) 0.02 0.63 (0.42, 0.93)
*The hazard model is: (20.7740) 3 VF 1 (20.3876) 3 Syncopal VT 5 (0.4304) 3 Hx of Cerebrovascular Disease 1
(20.0197) LVEF 1 (0.4998) 3 Hx of any Tachyarrhythmia 1 (20.4675) 3 Revascularization (For VF, syncopal VT, Hx of
Cerebrovascular Disease, Hx of any Tachyarrhythmia and Revascularization, 1 5 yes, 0 5 no. The first sextile is defined by
values from this model less than or equal to 1.4312.)
CI 5 confidence interval; EF 5 ejection fraction; Hx 5 history; ICD 5 implantable cardioverter defibrillation; LVEF 5 left
ventricular ejection fraction; VF 5 ventricular fibrillation; VT 5 ventricular tachyeardia.
Figure 1. Survival free of ventricular tachyarrhythmia for the first and for the second through sixth sextiles. ICD 5 implantable cardioverter defibrillator.
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tion between LVEF and presenting arrhythmia as a result of
the AVID entry criteria. To be eligible for AVID, VT
patients had to have EFs ,40%, while there was no EF
restriction for VF patients. Thus, VF patients were over-
represented in the EF .35% patient population. Our result
suggests that presenting arrhythmia may be at least as
important as LVEF in determining who may not benefit
from ICD implantation. A comparison of classification by
Table 2. Recurrent Arrhythmia and Survival Time by Sextile
Sextile
% With
Recurrent
Arrhythmia
Recurrent Arrhythmia Type Obtained
Shock for ATP for
VT
Hosp
Documentation
for VF/VT
Arrhythmic
Death
Mean (6 SE) Survival to Three Years
VF VT ICD AAD D
1 22.9 40% 34% 5.3% 5.3% 16% 2.74 6 0.08 2.71 6 0.10 0.03 6 0.12
2 38.0 14% 34% 12% 22% 19% 2.70 6 0.09 2.44 6 0.12 0.25 6 0.14
3 43.2 16% 48% 12% 12% 12% 2.67 6 0.09 2.50 6 0.12 0.18 6 0.15
4 46.0 11% 38% 11% 25% 15% 2.53 6 0.12 2.20 6 0.13 0.34 6 0.18
5 56.0 3.4% 42% 21% 25% 9% 2.62 6 0.10 2.44 6 0.12 0.18 6 0.16
6 56.6 5.6% 36% 23% 22% 13% 2.55 6 0.12 2.23 6 0.13 0.32 6 0.17
AAD 5 antiarrhythmic drug; ATP 5 antitachycardia pacing; ICD 5 implantable cardioverter defibrillator; VF 5 ventricular fibrillation; VT 5 ventricular tachycardia.
Figure 2. Survival (from death) by treatment arm for the first sextile (A) and for the second through sixth sextiles (B). AAD 5 antiarrhythmic drug; ICD 5
implantable cardioverter defibrillator.
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LVEF and sextile is shown in Table 5. Of the patients,
identified at low risk for recurrent arrhythmia 28% had
LVEF #0.35, while 22.7% of the patients identified at high
risk for recurrent arrhythmia had LVEF .0.35. Thus, there
is substantial nonoverlap.
Mortality was similar and moderately low in the sextile at
low risk of recurrent arrhythmia whether the patient was
treated with ICD or AAD (e.g., at two years, survival in the
ICD and AAD arms was 87% and 91% in the first sextile
and 82% and 74% in those not in the first sextile). The
equivalence of survival cannot be attributed to crossover by
addition of an ICD since only two of the 76 low arrhythmia
risk (first sextile) patients in the drug arm had received an
ICD by three years. It may be that amiodarone is relatively
Table 3. Baseline Characteristics That Differed Between the 1st and 2nd Through 6th Sextiles*
Hazard for Recurrent Arrhythmia
1st Sextile
(n 5 166)
2nd through
6th Sextiles
(n 5 818)
Age, yrs 61.6 65.7
Patient gender (%) Female 27.7 19.1
Ejection fraction (%)† 46.8 28.6
Index arrhythmia type (%)† CA from VF 92.2 34.1
Doc VT, Syncope 7.8 23.7
Symp Sust VT 42.2
Index arrhythmia in-hospital (%) 12.7 26.3
History of (%)
Diabetes 17.5 26.0
MI 49.4 70.5
Any prior tachyarrhythmia† 10.2 56.4
VF 1.2 5.1
VT 17.4
AF flutter 6.0 26.8
Bradycardia or AV block 1.2 7.2
Unexplained syncope 2.4 15.2
CHF 22.9 50.6
Peripheral vascular disease 9.0 16.7
Cerebrovascular disease† 0.6 17.0
Revascularization 27.7 37.3
Coronary artery disease (%) 73.5 82.8
Hypertrophic cardiomyopathy (%) 0.6 2.2
Nonischemic dilated cardiomyopathy (%) 4.2 16.9
CHF class III at baseline (%) 1.8 10.3
Present smoker (%) 29.5 19.3
*Characteristics that did not differ included: race, treatment for alcohol or drug, angina class at baseline, history of angina,
hypertension, chronic pulmonary disease, renal disease, thyroid disease, arthritis, neoplasm or depression; †Multivariate
predictors of hazard for recurrent arrhythmia.
AF 5 atrial flutter; AV 5 atrioventricular; CA 5 cardiac arrest; CHF 5 congestive heart failure; Doc 5 documented; MI 5
myocardial infarction; Symp 5 symptomatic; Sust 5 sustained; VF 5 ventricular fibrillation; VT 5 ventricular tachycardia.
Table 4. Discharge Medications and Procedures at Baseline Hospital Discharge
Hazard for Recurrent Arrhythmia
1st Sextile 2nd through 6th Sextile
(n 5 90)
Device
(n 5 76)
Drug
(n 5 399)
Device
(n 5 419)
Drug
ACE inhibitor (%) 46.7 48.7 73.9 72.6
Aspirin or antiplatelet (%) 68.9 67.1 59.1 56.8
Beta-blocker (nonsotalol) (%) 56.7 19.7 38.8 15.5
Calcium channel blocker (%) 16.7 23.7 18.0 10.5
Digitalis (%) 23.3 19.7 51.4 45.1
Diuretic (%) 26.7 25.0 52.9 56.8
Nitrate (%) 27.8 28.9 36.8 38.2
Warfarin (%) 5.6 15.8 22.6 36.8
Other vasodilator (%) 4.4 5.3 6.0 6.4
Pacemaker implant (%) 3.9 2.8 7.6
Revascularization (%)* 22.2 28.9 7.8 8.6
*Multivariate predictor of hazard for recurrent arrhythmia.
ACE 5 angiotensin-converting enzyme.
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more effective in this subgroup. Looking at clinically rele-
vant arrhythmias (criteria 2 and 3 in the first paragraph of
the Methods section), the arrhythmia recurrence rate at
three years in the drug arm was 12% in the first sextile and
35% in sextiles two through six, a ratio of 0.33 compared
with a ratio of 0.48 for the total arrhythmia recurrence rates
in the ICD arm. These ratios suggest amiodarone is
eliminating or rendering nonclinical proportionately more
of the “potential” arrhythmia or that proportionately more
of the arrhythmia are self-terminating (without an ICD to
intervene) with insufficient symptoms to cause hospitaliza-
tion in the first sextile.
We can only speculate as to why the identified criteria
might select patients who are at lower risk for recurrent
arrhythmia and seem to do as well on amiodarone as after
ICD implant. Survivors of VF might be expected to be the
most likely to benefit from an ICD given that survival after
a recurrence of VF is much less likely than from a recurrence
of VT. On the other hand, recurrences of VF, though
perhaps more likely to be fatal, are much less common than
recurrences of VT. On electrophysiologic testing, VT is a
much more reproducible finding than VF. Perhaps in many
patients VF is a one-time chance occurrence or is the result
of severe ischemia that is made less likely to occur by
revascularization. A history of cerebrovascular disease sug-
gested a higher rate of recurrence and higher mortality and
may similarly identify patients with more aggressive vascular
disease who are more likely to have a recurrence of an
ischemia triggered VF. A history of a prior arrhythmia was
also a risk factor and, though this group includes patients
with a history of atrial fibrillation, it may be most important
as a marker of a prior VT. In contrast with VF, VT is
usually a reproducible arrhythmia that is due to reentry
around myocardial scarring that is usually not eliminated by
anti-ischemic therapy. In this substrate, which would be
present in patients that present with VT or had had an
episode of VT in the past, arrhythmia is more likely to recur
and may be more resistant to the antiarrhythmic effects of
amiodarone and, thus, make the ICD relatively more
effective.
It is intriguing to consider whether these patients need
specific antiarrhythmic treatment at all. Indeed, of the 17
deaths in the 166 patients, 11 were classified by the events
committee to be nonarrhythmic. Based on a Cox propor-
tional hazards survival model of mortality in the 166
patients at low risk of recurrent arrhythmia, higher Cana-
dian Cardiovascular Class for angina at baseline (relative
hazards [rh] approximately 1.5), index event in-hospital
(rh 5 7.6) and a history of renal disease (rh 5 7.0) were
predictive of mortality. Adjusting for these baseline predic-
tors, among discharge medications and procedures per-
formed during the baseline hospitalization, nitrates (rh 5
2.9) and calcium channel blockers (rh 5 3.0) were predictive
of mortality. Most of these factors suggest that the deaths
may have been secondary to ischemia. Again, perhaps
amiodarone is relatively more effective in these patients
because of its antiadrenergic or anti-ischemia properties.
The similar efficacy of amiodarone and beta-adrenergic
blocking agents in the Hamburg ICD trial may be further
evidence that the anti-ischemic effects of amiodarone may
be more important in this subgroup of patients.
A weakness of this study is that, although the general
approach to determining our subgroup criteria were planned
before collecting the data, the specific criteria for defining
the subgroups were data-derived. Thus, the results must be
considered speculative and need to be verified prospectively
in other datasets. However, while the method used in this
paper has the potential to produce a biased estimate of the
benefit of ICD related to the inability to develop the
prediction model in both groups, the bias tends to inflate
the benefit of the ICD at the lowest sextile of risk, relative
to the other sextiles. Thus, the conclusions drawn in this
paper may be conservative.
A second weakness is that these data do not speak to the
issue of a relative benefit of the ICD beyond three years. It
does, though, seem unlikely that there will be a large
number of patients who will have their first recurrence of
VF or VT more than three years after their index event.
In summary, patients presenting with an isolated episode
of VF in the absence of cerebrovascular disease or history of
prior arrhythmia who have undergone revascularization or
who have moderately preserved left ventricular function
(LVEF . 0.27) are not likely to benefit from ICD therapy
compared with amiodarone therapy. Treatment consider-
ations for these patients should include: 1) amiodarone as a
reasonable alternative therapy to ICDs, especially if there
are clinical, financial, logistical, social or psychological
reasons to avoid ICD therapy; and 2) focus on therapy for
nonarrhythmic mortality risks, especially ischemia.
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